Pacific Edge Named in TIN Report Top 10 List

18 October 2017
COMPANY ANNOUNCEMENT
Pacific Edge Named in TIN Report Top 10 List

Pacific Edge named number 6 in TIN Top Ten Hot Emerging Companies for 2017
Pacific Edge’s global growth and positive revenue trajectory has been recognised with the cancer
diagnostics company named number 6 in the TIN Top Ten List of Hot Emerging Companies for 2017.

Technology Investment Network produces the annual TIN Report tracking the progress of New
Zealand's technology companies, and selection is based on revenue growth for FY17. The TIN Top Ten
Hot Emerging Companies for 2017 includes firms with revenues between $8.2 million and $16 million,
with a collective revenue increase of 37%
1
.

The top companies by revenue growth were named at an event in Auckland last night. A number of the
high growth companies named, including Pacific Edge, are gaining traction and exposure in the US. TIN
managing director, Greg Shanahan, noted that it was indicative of “a growing level of expertise and
understanding of how to grow a global business. In a first for New Zealand, TIN200 companies’ total
revenue now exceeds $10 billion, making them third in contribution to New Zealand’s GDP behind dairy
and tourism.”

Pacific Edge has been building its commercial business of the US market over the past four years and
now has an effective strategy that it is using to build awareness, trial and gain commercial adoption of its
innovative bladder cancer diagnostic tests. A number of significant milestones were achieved in 2016
including the completion of the Federal Supply schedule, the Veteran’s Administration and TRICARE
contract enabling access to the US’s active military and veterans, and increasing the product suite to
four novel molecular diagnostic tests.

Pacific Edge’s successful progress in the implementation of its strategy since launching in the US in mid-
2013 is reflected in the significant uplift in commercial revenue in the past two years.

Pacific Edge CEO, David Darling, says: “Our portfolio of Cxbladder products is now in the market with
Cxbladder Resolve launching in NZ in late 2016 and planned for launch in the USA late this year. Having
four molecular diagnostic products across the clinical diagnosis and management pathway for urothelial
cancer is a global first for any company.”

“Cxbladder is being adopted at an increasing pace by urologists in our key markets. Medical products by
their very nature have a high threshold of proof of performance before mainstream adoption and it is
great to see this happening now particularly in our home country of New Zealand.”

“We were pleased to see our positive progress recognised again in the TIN Report announced last night.
We are a small company and our team continues to punch well above its weight in the global market.
We remain firmly focused on high growth.”

ENDS

For more information contact:

David Darling
Chief Executive Officer
Pacific Edge Ltd
P: +64 (3) 479 5800


1
TIN Report 2017, 13
th
Edition, Technology Industry Analysis

18 October 2017
COMPANY ANNOUNCEMENT
OVERVIEW www.pacificedgedx.com
Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and
commercialisation of diagnostic and prognostic tests for better detection and management of cancer. The company is
developing and commercialising its range of Cxbladder bladder cancer tests globally through its wholly owned central
laboratories in New Zealand and the USA. The company’s products have been tested and validated in international multi-
centre clinical studies.

Pacific Edge has four proprietary, novel, accurate, molecular diagnostic products in-market providing actionable results, and
better detection and management of urothelial cancer. Cxbladder Triage, Detect and Monitor are available through the
company’s dedicated CLIA-certified laboratories for customers in New Zealand, Australia, Singapore and the USA. Cxbladder
Resolve launched in New Zealand in December 2016.

ABOUT Cxbladder Triage www.cxbladder.com
Cxbladder Triage combines the power of the genomic biomarkers with additional phenotypic and clinical risk factors to
accurately identify patients with haematuria who have a low probability of bladder cancer and may not require a more
extensive urological evaluation. Cxbladder Triage is a tool for use by clinicians and physicians in primary evaluation of
patients with haematuria and is intended to reduce the need for an expensive and invasive work-up in patients who have a
low probability of having urothelial carcinoma.

ABOUT Cxbladder Detect www.cxbladder.com
Cxbladder Detect enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of a
patients’ urine. Cxbladder Detect was launched in 2013 in the USA and is commercially available in New Zealand, Australia
and the USA as a Laboratory Developed Test (LDT) from the company’s CLIA certified laboratories. Cxbladder Detect provides
clinicians with a quick, cost effective and accurate measure of the presence of the cancer as an effective adjunct to
cystoscopy.

ABOUT Cxbladder Monitor www.cxbladder.com
Cxbladder Monitor, the third test in the Cxbladder portfolio for urologists, is a proprietary, non-invasive, molecular diagnostic
test that combines genomic biomarkers measured from a small quantity of a patient’s urine, with patient specific clinical
factors to better monitor bladder cancer patients for recurrence. Bladder cancer has a recurrence rate of 50-80% and
requires life-long surveillance. Cxbladder Monitor accurately identifies patients with a prior history of urothelial cancer (UC)
whose Cxbladder Monitor score shows that they have a low probability of recurrent urothelial carcinoma. Cxbladder Monitor
is designed to be used as the preferred adjunct test to cystoscopy in the management of patients for ongoing evaluation of
recurrent bladder cancer.

ABOUT Cxbladder Resolve www.cxbladder.com
Cxbladder Resolve is a proprietary, non-invasive, molecular diagnostic test that combines genomic biomarkers measured
from a small quantity of a patient’s urine, with patient characteristics for the identification of patients who are likely to have
aggressive or more advanced bladder cancer. Cxbladder Resolve, when used as part of the primary evaluation of haematuria
and/or in conjunction with other Cxbladder tests (Triage, Detect), is designed to assist clinicians by accurately identifying
patients with a high probability of having high grade or late stage bladder cancer, for whom alternative or expedited
treatment options may be warranted, or who can be prioritised for further investigation in high throughput settings.

Refer to www.cxbladder.com for more information.